Literature DB >> 16868991

Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms.

Gregg J Silverman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16868991     DOI： 10.1002/art.22020

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  15 in total

Review 1.  B cell modulation in rheumatology.

Authors:  Gregg J Silverman; Sahil Khanna
Journal:  Curr Opin Pharmacol       Date:  2007-07-10       Impact factor: 5.547

2.  B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas.

Authors:  Nesrine I Affara; Brian Ruffell; Terry R Medler; Andrew J Gunderson; Magnus Johansson; Sophia Bornstein; Emily Bergsland; Martin Steinhoff; Yijin Li; Qian Gong; Yan Ma; Jane F Wiesen; Melissa H Wong; Molly Kulesz-Martin; Bryan Irving; Lisa M Coussens
Journal:  Cancer Cell       Date:  2014-06-05       Impact factor: 31.743

3.  Atacicept: targeting B cells in multiple sclerosis.

Authors:  Hans-Peter Hartung; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2010-07       Impact factor: 6.570

Review 4.  [Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis].

Authors:  H-P Hartung
Journal:  Nervenarzt       Date:  2009-12       Impact factor: 1.214

Review 5.  Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.

Authors:  M C Levesque
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

6.  Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome.

Authors:  Catherine Melander; Marion Sallée; Pierre Trolliet; Sophie Candon; Xavier Belenfant; Eric Daugas; Phillipe Rémy; Virginie Zarrouk; Evangéline Pillebout; Christian Jacquot; Jean-Jacques Boffa; Alexandre Karras; Virginie Masse; Philippe Lesavre; Caroline Elie; Isabelle Brocheriou; Bertrand Knebelmann; Laure-Hélène Noël; Fadi Fakhouri
Journal:  Clin J Am Soc Nephrol       Date:  2009-03-04       Impact factor: 8.237

Review 7.  Polarized immune responses differentially regulate cancer development.

Authors:  Magnus Johansson; David G Denardo; Lisa M Coussens
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

8.  Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results.

Authors:  A Kavanaugh; S Rosengren; S J Lee; D Hammaker; G S Firestein; K Kalunian; N Wei; D L Boyle
Journal:  Ann Rheum Dis       Date:  2007-07-20       Impact factor: 19.103

9.  Targeted therapies in rheumatoid arthritis: Focus on rituximab.

Authors:  Y K Teng; T W Huizinga; J M van Laar
Journal:  Biologics       Date:  2007-12

10.  Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis.

Authors:  Gianfranco Ferraccioli; Barbara Tolusso; Francesca Bobbio-Pallavicini; Elisa Gremese; Viviana Ravagnani; Maurizio Benucci; Edoardo Podestà; Fabiola Atzeni; Alice Mannocci; Domenico Biasi; Mariangela Manfredi; Piercarlo Sarzi-Puttini; Bruno Laganà; Carlomaurizio Montecucco
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.